Discrimination: standardized mean difference in ASDAS scores between patients with high and low disease activity
| . | PASSa (N = 381 patients, 912 observations) . | PASS physicianb (N = 138 patients, 471 observations) . | PhGAc (N = 854 patients, 2830 observations) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | High DA . | Low DA . | . | High DA . | Low DA . | . | High DA . | Low DA . | . |
| . | PASS = no [mean (s.d.)] . | PASS = yes [mean (s.d.)] . | SMD . | PASS physician = no [mean (s.d.)] . | PASS physician = yes [mean (s.d.)] . | SMD . | PhGA >4 [mean (s.d.)] . | PhGA ≤4 [mean (s.d.)] . | SMD . |
| Original-ASDA | 3.19 (0.97) | 1.86 (0.88) | 1.43 | 2.78 (0.83) | 1.82 (0.86) | 1.13 | 3.15 (1.05) | 2.12 (0.99) | 1.00 |
| ASDAS-Q1 | 3.02 (0.90) | 1.80 (0.87) | 1.37 | 2.58 (0.80) | 1.74 (0.84) | 1.02 | 2.92 (0.98) | 2.05 (0.94) | 0.91 |
| ASDAS-Q2 | 3.08 (0.97) | 1.82 (0.93) | 1.33 | 2.65 (0.83) | 1.74 (0.89) | 1.06 | 3.02 (1.03) | 2.06 (1.00) | 0.94 |
| ASDAS-Q14 | 3.08 (0.94) | 1.80 (0.89) | 1.39 | 2.60 (0.82) | 1.74 (0.87) | 1.02 | 2.98 (1.01) | 2.05 (0.97) | 0.93 |
| ASDAS-Q23 | 3.05 (0.99) | 1.78 (0.92) | 1.32 | 2.58 (0.86) | 1.71 (0.89) | 1.00 | 2.97 (1.05) | 2.02 (1.00) | 0.93 |
| ASDAS-Q26 | 3.09 (1.00) | 1.80 (0.92) | 1.34 | 2.63 (0.85) | 1.71 (0.87) | 1.06 | 2.99 (1.05) | 2.05 (1.00) | 0.92 |
| ASDAS-Q145 | 3.13 (0.96) | 1.82 (0.91) | 1.40 | 2.66 (0.84) | 1.77 (0.89) | 1.04 | 3.03 (1.03) | 2.07 (0.99) | 0.95 |
| ASDAS-Q236 | 3.10 (1.01) | 1.80 (0.93) | 1.34 | 2.61 (0.87) | 1.71 (0.88) | 1.02 | 3.00 (1.07) | 2.04 (1.01) | 0.92 |
| ASDAS-BT | 3.15 (0.99) | 1.83 (0.93) | 1.37 | 2.67 (0.86) | 1.76 (0.90) | 1.03 | 3.05 (1.06) | 2.08 (1.00) | 0.94 |
| ASDAS-C3 | 3.02 (0.98) | 1.71 (0.94) | 1.36 | 2.56 (0.86) | 1.64 (0.90) | 1.04 | 2.94 (1.05) | 1.97 (1.02) | 0.93 |
| . | PASSa (N = 381 patients, 912 observations) . | PASS physicianb (N = 138 patients, 471 observations) . | PhGAc (N = 854 patients, 2830 observations) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | High DA . | Low DA . | . | High DA . | Low DA . | . | High DA . | Low DA . | . |
| . | PASS = no [mean (s.d.)] . | PASS = yes [mean (s.d.)] . | SMD . | PASS physician = no [mean (s.d.)] . | PASS physician = yes [mean (s.d.)] . | SMD . | PhGA >4 [mean (s.d.)] . | PhGA ≤4 [mean (s.d.)] . | SMD . |
| Original-ASDA | 3.19 (0.97) | 1.86 (0.88) | 1.43 | 2.78 (0.83) | 1.82 (0.86) | 1.13 | 3.15 (1.05) | 2.12 (0.99) | 1.00 |
| ASDAS-Q1 | 3.02 (0.90) | 1.80 (0.87) | 1.37 | 2.58 (0.80) | 1.74 (0.84) | 1.02 | 2.92 (0.98) | 2.05 (0.94) | 0.91 |
| ASDAS-Q2 | 3.08 (0.97) | 1.82 (0.93) | 1.33 | 2.65 (0.83) | 1.74 (0.89) | 1.06 | 3.02 (1.03) | 2.06 (1.00) | 0.94 |
| ASDAS-Q14 | 3.08 (0.94) | 1.80 (0.89) | 1.39 | 2.60 (0.82) | 1.74 (0.87) | 1.02 | 2.98 (1.01) | 2.05 (0.97) | 0.93 |
| ASDAS-Q23 | 3.05 (0.99) | 1.78 (0.92) | 1.32 | 2.58 (0.86) | 1.71 (0.89) | 1.00 | 2.97 (1.05) | 2.02 (1.00) | 0.93 |
| ASDAS-Q26 | 3.09 (1.00) | 1.80 (0.92) | 1.34 | 2.63 (0.85) | 1.71 (0.87) | 1.06 | 2.99 (1.05) | 2.05 (1.00) | 0.92 |
| ASDAS-Q145 | 3.13 (0.96) | 1.82 (0.91) | 1.40 | 2.66 (0.84) | 1.77 (0.89) | 1.04 | 3.03 (1.03) | 2.07 (0.99) | 0.95 |
| ASDAS-Q236 | 3.10 (1.01) | 1.80 (0.93) | 1.34 | 2.61 (0.87) | 1.71 (0.88) | 1.02 | 3.00 (1.07) | 2.04 (1.01) | 0.92 |
| ASDAS-BT | 3.15 (0.99) | 1.83 (0.93) | 1.37 | 2.67 (0.86) | 1.76 (0.90) | 1.03 | 3.05 (1.06) | 2.08 (1.00) | 0.94 |
| ASDAS-C3 | 3.02 (0.98) | 1.71 (0.94) | 1.36 | 2.56 (0.86) | 1.64 (0.90) | 1.04 | 2.94 (1.05) | 1.97 (1.02) | 0.93 |
Analysis was repeated with different anchors (PASS, PASS physician, PhGA).
Only available in SPACE and NOR-DMARD;
only available in SPACE;
available in all cohorts except ASSERT. The alternative-ASDAS formulae were calculated using, as a replacement for PGA: question 1 (Q1), Q2, average of Q1 and Q4 (Q14) or Q2 and Q3 (Q23) or Q2 and Q6 (Q26), average of questions Q1, Q4 and Q5 (Q145) or Q2, Q3 and Q6 (Q236) and total score (BT) of the BASDAI, or a constant (-C3). ASDAS: Ankylosing Spondylitis Disease Activity Scores; original-ASDAS: ASDAS according to the usual formula [5, 6]; PASS: Patient Acceptable Symptom State; PASS physician: Physician Acceptable Symptom State; PhGA: Physician Global Assessment of disease activity; SMD: standardized mean difference; SPACE: SPondyloArthritis Caught Early; NOR-DMARD: Norwegian Disease-Modifying Antirheumatic Drug study; ASSERT: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy.
Discrimination: standardized mean difference in ASDAS scores between patients with high and low disease activity
| . | PASSa (N = 381 patients, 912 observations) . | PASS physicianb (N = 138 patients, 471 observations) . | PhGAc (N = 854 patients, 2830 observations) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | High DA . | Low DA . | . | High DA . | Low DA . | . | High DA . | Low DA . | . |
| . | PASS = no [mean (s.d.)] . | PASS = yes [mean (s.d.)] . | SMD . | PASS physician = no [mean (s.d.)] . | PASS physician = yes [mean (s.d.)] . | SMD . | PhGA >4 [mean (s.d.)] . | PhGA ≤4 [mean (s.d.)] . | SMD . |
| Original-ASDA | 3.19 (0.97) | 1.86 (0.88) | 1.43 | 2.78 (0.83) | 1.82 (0.86) | 1.13 | 3.15 (1.05) | 2.12 (0.99) | 1.00 |
| ASDAS-Q1 | 3.02 (0.90) | 1.80 (0.87) | 1.37 | 2.58 (0.80) | 1.74 (0.84) | 1.02 | 2.92 (0.98) | 2.05 (0.94) | 0.91 |
| ASDAS-Q2 | 3.08 (0.97) | 1.82 (0.93) | 1.33 | 2.65 (0.83) | 1.74 (0.89) | 1.06 | 3.02 (1.03) | 2.06 (1.00) | 0.94 |
| ASDAS-Q14 | 3.08 (0.94) | 1.80 (0.89) | 1.39 | 2.60 (0.82) | 1.74 (0.87) | 1.02 | 2.98 (1.01) | 2.05 (0.97) | 0.93 |
| ASDAS-Q23 | 3.05 (0.99) | 1.78 (0.92) | 1.32 | 2.58 (0.86) | 1.71 (0.89) | 1.00 | 2.97 (1.05) | 2.02 (1.00) | 0.93 |
| ASDAS-Q26 | 3.09 (1.00) | 1.80 (0.92) | 1.34 | 2.63 (0.85) | 1.71 (0.87) | 1.06 | 2.99 (1.05) | 2.05 (1.00) | 0.92 |
| ASDAS-Q145 | 3.13 (0.96) | 1.82 (0.91) | 1.40 | 2.66 (0.84) | 1.77 (0.89) | 1.04 | 3.03 (1.03) | 2.07 (0.99) | 0.95 |
| ASDAS-Q236 | 3.10 (1.01) | 1.80 (0.93) | 1.34 | 2.61 (0.87) | 1.71 (0.88) | 1.02 | 3.00 (1.07) | 2.04 (1.01) | 0.92 |
| ASDAS-BT | 3.15 (0.99) | 1.83 (0.93) | 1.37 | 2.67 (0.86) | 1.76 (0.90) | 1.03 | 3.05 (1.06) | 2.08 (1.00) | 0.94 |
| ASDAS-C3 | 3.02 (0.98) | 1.71 (0.94) | 1.36 | 2.56 (0.86) | 1.64 (0.90) | 1.04 | 2.94 (1.05) | 1.97 (1.02) | 0.93 |
| . | PASSa (N = 381 patients, 912 observations) . | PASS physicianb (N = 138 patients, 471 observations) . | PhGAc (N = 854 patients, 2830 observations) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | High DA . | Low DA . | . | High DA . | Low DA . | . | High DA . | Low DA . | . |
| . | PASS = no [mean (s.d.)] . | PASS = yes [mean (s.d.)] . | SMD . | PASS physician = no [mean (s.d.)] . | PASS physician = yes [mean (s.d.)] . | SMD . | PhGA >4 [mean (s.d.)] . | PhGA ≤4 [mean (s.d.)] . | SMD . |
| Original-ASDA | 3.19 (0.97) | 1.86 (0.88) | 1.43 | 2.78 (0.83) | 1.82 (0.86) | 1.13 | 3.15 (1.05) | 2.12 (0.99) | 1.00 |
| ASDAS-Q1 | 3.02 (0.90) | 1.80 (0.87) | 1.37 | 2.58 (0.80) | 1.74 (0.84) | 1.02 | 2.92 (0.98) | 2.05 (0.94) | 0.91 |
| ASDAS-Q2 | 3.08 (0.97) | 1.82 (0.93) | 1.33 | 2.65 (0.83) | 1.74 (0.89) | 1.06 | 3.02 (1.03) | 2.06 (1.00) | 0.94 |
| ASDAS-Q14 | 3.08 (0.94) | 1.80 (0.89) | 1.39 | 2.60 (0.82) | 1.74 (0.87) | 1.02 | 2.98 (1.01) | 2.05 (0.97) | 0.93 |
| ASDAS-Q23 | 3.05 (0.99) | 1.78 (0.92) | 1.32 | 2.58 (0.86) | 1.71 (0.89) | 1.00 | 2.97 (1.05) | 2.02 (1.00) | 0.93 |
| ASDAS-Q26 | 3.09 (1.00) | 1.80 (0.92) | 1.34 | 2.63 (0.85) | 1.71 (0.87) | 1.06 | 2.99 (1.05) | 2.05 (1.00) | 0.92 |
| ASDAS-Q145 | 3.13 (0.96) | 1.82 (0.91) | 1.40 | 2.66 (0.84) | 1.77 (0.89) | 1.04 | 3.03 (1.03) | 2.07 (0.99) | 0.95 |
| ASDAS-Q236 | 3.10 (1.01) | 1.80 (0.93) | 1.34 | 2.61 (0.87) | 1.71 (0.88) | 1.02 | 3.00 (1.07) | 2.04 (1.01) | 0.92 |
| ASDAS-BT | 3.15 (0.99) | 1.83 (0.93) | 1.37 | 2.67 (0.86) | 1.76 (0.90) | 1.03 | 3.05 (1.06) | 2.08 (1.00) | 0.94 |
| ASDAS-C3 | 3.02 (0.98) | 1.71 (0.94) | 1.36 | 2.56 (0.86) | 1.64 (0.90) | 1.04 | 2.94 (1.05) | 1.97 (1.02) | 0.93 |
Analysis was repeated with different anchors (PASS, PASS physician, PhGA).
Only available in SPACE and NOR-DMARD;
only available in SPACE;
available in all cohorts except ASSERT. The alternative-ASDAS formulae were calculated using, as a replacement for PGA: question 1 (Q1), Q2, average of Q1 and Q4 (Q14) or Q2 and Q3 (Q23) or Q2 and Q6 (Q26), average of questions Q1, Q4 and Q5 (Q145) or Q2, Q3 and Q6 (Q236) and total score (BT) of the BASDAI, or a constant (-C3). ASDAS: Ankylosing Spondylitis Disease Activity Scores; original-ASDAS: ASDAS according to the usual formula [5, 6]; PASS: Patient Acceptable Symptom State; PASS physician: Physician Acceptable Symptom State; PhGA: Physician Global Assessment of disease activity; SMD: standardized mean difference; SPACE: SPondyloArthritis Caught Early; NOR-DMARD: Norwegian Disease-Modifying Antirheumatic Drug study; ASSERT: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
